Harbour BioMed-B (02142.HK) Enters Evaluation and License Agreement with Umoja Biopharma to Advance In Vivo CAR-T Therapies

Intelligent Finance APP, HARBOR PHARMA-B (02142) announced that its wholly-owned subsidiary, Harbour BioMed (Suzhou) Co., Ltd. ("Harbour BioMed"), has entered into an Evaluation and License Agreement (the "Agreement") with Umoja Biopharma, Inc. ("Umoja Biopharma") to utilize Harbour BioMed’s HCAb Harbour Mice.^®Platform and NonaCarFx^TMPlatform and Umoja Biopharma's VivoVec^TMCombined with the platform, they will jointly advance the development of multiple in vivo CAR-T cell products. The agreement marks a further deepening and expansion of the strategic partnership established between the two companies in September 2024.

According to the terms of the agreement, Harbour BioMed (Suzhou) Co., Ltd. will be entitled to receive an upfront payment, potential option fees, and milestone payments related to the discovery and development of collaboration projects. Umoja Biopharma will be responsible for all subsequent product development and commercialization efforts.

Umoja Biopharma, Inc. is a clinical-stage biotechnology company dedicated to developing more accessible and effective in vivo CAR-T cell therapies in the fields of oncology and autoimmune diseases. Umoja Biopharma's VivoVec^TMIn vivo gene delivery technology can enhance the ability of a patient's own immune system to combat diseases. Supporting its core technology is the company’s advanced lentiviral vector development and manufacturing facility located in Louisville, Colorado, USA. Umoja Biopharma believes that its scientific research can improve the accessibility and effectiveness of immunotherapy, helping more patients lead better and fuller lives.